Clinical Trials Logo

Clinical Trial Summary

To study the feasibility of using magnetic resonance imaging (MRI) in evaluation UB wall thickening after transurethral resection (TUR) of bladder cancer.


Clinical Trial Description

Urinary bladder carcinoma is the second most common tumour of the urinary tract and 70% of such carcinomas are non-muscle-invasive (superficial) at presentation. Transurethral resection (TUR) is the standard treatment; however, recurrence of the tumour is not uncommon so such patients require long-term close supervision. Staging is based on TNM system. Ta tumors are treated with transurethral resection of bladder tumor (TUR-BT). T1 and carcinoma in situ (Tis) tumors have risk of progression and intravesical immunotherapy with Bacillus-Calmette-Guerin (BCG) instillations is used to obtain local control and organ preservation. Invasive bladder cancer (MIBC) is an aggressive disease and standard treatment is radical cystectomy (RC), accompanied by pelvic lymph node dissection (PLND). In addition to radical surgery, neoadjuvant chemotherapy (NAC) has been demonstrated to increase overall survival in MIBC and is recommended by consensus guidelines. Compared to contrast enhanced CT, MRI has better soft tissue contrast which may improve local tumor evaluation. Surveillance strategies for urinary bladder carcinoma recurrence have historically relied on cystoscopy, but this procedure has drawbacks, including its high cost, invasiveness and the fact that it may lead to iatrogenic bladder injury and urinary sepsis. In addition, it cannot diagnose upper tract tumours. The presence of a radiological method that could differentiate between benign and malignant lesions of the bladder would avoid the need for invasive cystoscopy, provided that upper tract tumours were excluded. Diffusion-weighted (DW) MRI is a non-invasive technique measuring the microscopic mobility of water molecules in the tissues without contrast administration. It provides information on perfusion and diffusion simultaneously in any organ, so it can be used to differentiate normal and abnormal structures of tissues, and it might help in the characterization of various abnormalities. During follow-up of patients after trans-urethral resection (TUR), it is difficult to distinguish residual cancer from fibrotic and inflammatory changes secondary to TUR and intravesical chemotherapy, both of which manifest as bladder wall thickening on T2-weighted MRI. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05787938
Study type Observational
Source Assiut University
Contact Ayat Ibrahim, Resident Doctor
Phone 01068306016
Email ayatibrahim59@yahoo.com
Status Not yet recruiting
Phase
Start date April 1, 2023
Completion date December 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT00872495 - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Withdrawn NCT05335707 - Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
Completed NCT03998579 - Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer N/A
Not yet recruiting NCT04525781 - Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
Completed NCT02897765 - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Phase 1
Recruiting NCT05822934 - Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer Phase 3
Completed NCT06156787 - Patterns of Urinary Bladder Cancer in Darfur, Suda
Completed NCT02722538 - Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Phase 1
Completed NCT02437539 - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 1
Completed NCT02139371 - Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 0
Completed NCT03433924 - An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
Active, not recruiting NCT03132922 - MAGE-A4ᶜ¹º³²T for Multi-Tumor Phase 1
Completed NCT05946369 - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Recruiting NCT06307704 - Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients N/A
Completed NCT00462488 - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ Phase 2
Recruiting NCT05621837 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Recruiting NCT05644041 - Intravesical Gemcitabine in Patients With NMIBC Phase 2
Completed NCT04635566 - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute N/A
Recruiting NCT04861584 - Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects Phase 2
Completed NCT01836978 - Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy N/A